Rafi Emmanuel

Rafi Emmanuel

Company: Emendo Biotherapeutics

Job title: Senior Vice President, R&D


EMD-101, A Potential Autologous HSC-Based Therapy for ELANE-Related Severe Congenital Neutropenia 11:45 am

EMD-101 is a patient-derived HSCs product with a specific knock-out of ELANE mutated allele, that reverts the block of myeloid differentiation, typical of severe congenital neutropenia (SCN) The editing profile of our product undergoes a thorough genomic analysis to meet the highest safety standards Our product maintains the core functions of neutrophils in vitro, in…Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.